Apollo Medical Holdings, Inc. reported a strong third quarter with a 26% increase in total revenue and a 105% increase in net income attributable to ApolloMed. The company also raised its full-year 2021 guidance due to continued organic growth and increased risk pool settlements and incentives revenue.
Q3 total revenue increased by 26% year-over-year to $227.1 million.
Q3 net income attributable to ApolloMed increased by 105% year-over-year to $34.3 million.
Q3 earnings per share (diluted) increased by 64% year-over-year to $0.74.
Full-year 2021 guidance was raised due to organic growth and increased risk pool settlements.
ApolloMed raised its full-year 2021 guidance for total revenue, net income, net income attributable to ApolloMed, EBITDA, and adjusted EBITDA.
Analyze how earnings announcements historically affect stock price performance